Infectious Disease

Findings from a recent study show a broad spectrum of possible clinical manifestations of IRD following SARS-CoV-2 infection or COVID-19 vaccination.

The expanded labeling for the antiviral against COVID-19 indicates no dose adjustment is required for persons across all stages of liver disease.

A large study of hospitalized children with SARS-CoV-2 infection found that disease severity varied by age over the course of the COVID-19 pandemic.

The USPSTF particularly emphasizes effective communication with patients, including adherence support and calls for reducing barriers to PrEP for racial, ethnic, and other minority groups.

The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.

Patients hospitalized with COVID-19 were 2-times more likely to develop persistent hypertension than their influenza counterparts, according to results.

See highlights of CDC 2023 immunization updates for: pneumococcal disease; measles, mumps, and rubella; hepatitis B; polio; and monkeypox.

The CDC update recommends ending screening strategies that require multiple clinic visits for sample collection, favoring 1 visit and automatic HCV RNA testing.

A daily dose of clinical news on Patient Care you may have missed.

Updates to CDC recommendations on influenza and COVID-19 vaccines and vaccine formulations will impact your choices during flu season this year.

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?

A Vaccines for Adults program was proposed in the 2023 US federal budget and is proposed again for 2024. It is time for a VFA and this slide show highlights why.

Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.

More research is needed to determine whether metformin is also effective in patients with lower body mass index or with previous infection, said researchers.

Your daily dose of clinical news you may have missed.

Children hospitalized for RSV with LRTI during infancy have increased symptoms and lung function abnormalities, including increased resistance and decreased compliance.

Primary care clinicians will often be the first challenged to recognize neurologic sequelae of COVID-19; here's how to maximize short visits to assess long COVID.

Medical director of the NFID William Schaffner, MD, shares 3 things about the RSV vaccine that should be top of mind for primary care clinicians.

Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.

The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Researchers found a total of 12 symptoms that contributed to the long COVID scoring system.

Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.

The FDA approved Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.

Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

The US health care provider community continues to do its collective best to cope with the protean condition that is long COVID, according to recent poll findings.